New Biosimilars 2016 Many Indications Based on Few RCTs FDA – Arthritis Advisory Committees presentations 2016 BiosimilarOriginatorPharmaRCTsExtrapolations*Date InflectraRemicadeCelltrion AS RA RA & JIA Pso & PsA, AS CD & UC April 2016 ErelziEnbrel Sandoz/ Novartis Pso RA & JIA PsO & PsA, AS August 2016 AmjevitaHumiraAmgen RA Pso RA & JIA Pso & PsA, AS CD & UC Sept 2016 * Not all indications (pediatic Crohns, uveitis, hidradenitis supprativa) 3 TNF Inhibitor Biosimilars were FDA approved in 2016